Platelets from donors with consistently low HLA-B8, -B12, or -B35 expression do not undergo antibody-mediated internalization

Blood

Volumn 131, Issue 1, 2018, Pages 144-152

  Saris, Anno ^a,b   Tomson, Bert ^c   Brand, Anneke ^d   Mulder, Arend ^d   Claas, Frans H ^d   Lorinser, Jos ^c   Scharenberg, John ^a,b   Van Ham, S Marieke ^a,b   Ten Brinke, Anja ^a,b   Zwaginga, Jaap Jan ^a,d   Van Der Meer, Pieter F ^a,c,d  

^a SANQUIN RESEARCH   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c CENTRAL LABORATORY   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN CLASS 1; HLA B12 ANTIGEN; HLA B35 ANTIGEN; HLA B8 ANTIGEN; HUMAN MONOCLONAL ANTIBODY; THROMBOCYTE ANTIGEN; UNCLASSIFIED DRUG; ALLOANTIBODY; HLA B ANTIGEN; HLA-B12 ANTIGEN;

ANTIBODY MEDIATED INTERNALIZATION; ANTIBODY PRODUCTION; ANTIGEN EXPRESSION; ANTIGENIC VARIATION; ARTICLE; BLOOD DONOR; BLOOD SAMPLING; CONTROLLED STUDY; FALSE NEGATIVE RESULT; HLA MATCHING; HLA TYPING; HUMAN; HUMAN CELL; IN VIVO STUDY; INTERNALIZATION; MACROPHAGE; OPSONIZATION; PRIORITY JOURNAL; THROMBOCYTE TRANSFUSION; ZYGOSITY; DONOR; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; METABOLISM; PATIENT SELECTION; STANDARDS; THROMBOCYTE;

BLOOD PLATELETS; HISTOCOMPATIBILITY TESTING; HLA-B ANTIGENS; HLA-B35 ANTIGEN; HLA-B8 ANTIGEN; HUMANS; ISOANTIBODIES; MACROPHAGES; PATIENT SELECTION; PLATELET TRANSFUSION; TISSUE DONORS;

EID: 85040028773     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2017-07-799270     Document Type: Article

References (33)

1. Seftel MD, Growe GH, Petraszko T, et al. Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness. Blood. 2004;103(1):333-339.
2. Bilgin YM, van de Watering LMG, Brand A. Clinical effects of leucoreduction of blood transfusions. Neth J Med. 2011;69(10): 441-450.
3. Trial to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med. 1997;337(26): 1861-1869.
4. Kerkhoffs JLH, Eikenboom JCJ, van de Watering LMG, van Wordragen-Vlaswinkel RJ, Wijermans PW, Brand A. The clinical impact of platelet refractoriness: correlation with bleeding and survival. Transfusion. 2008; 48(9):1959-1965.
5. Slichter SJ, Davis K, Enright H, et al. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood. 2005;105(10):4106-4114.
6. Stanworth SJ, Navarrete C, Estcourt L, Marsh J. Platelet refractoriness-practical approaches and ongoing dilemmas in patient management. Br J Haematol. 2015;171(3):297-305.
7. Pavenski K, Freedman J, Semple JW. HLA alloimmunization against platelet transfusions: pathophysiology, significance, prevention and management. Tissue Antigens. 2012; 79(4):237-245.
8. Badlou BA, Wu YP, Smid WM, Akkerman J-WN. Platelet binding and phagocytosis by macrophages. Transfusion. 2006;46(8): 1432-1443.
9. Grozovsky R, Hoffmeister KM, Falet H. Novel clearance mechanisms of platelets. Curr Opin Hematol. 2010;17(6):585-589.
10. Crow AR, Lazarus AH. Role of Fcgamma receptors in the pathogenesis and treatment of idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol. 2003;25(suppl 1): 14-18.
11. Rebulla P. A mini-review on platelet refractoriness. Haematologica. 2005;90(2): 247-253.
12. Engelfriet CP, Reesink HW, Aster RH, et al. Management of alloimmunized, refractory patients in need of platelet transfusions. Vox Sang. 1997;73(3):191-198.
13. Lux A, Yu X, Scanlan CN, Nimmerjahn F. Impact of immune complex size and glycosylation on IgG binding to human FcgRs. J Immunol. 2013;190(8):4315-4323.
14. Leidi M, Gotti E, Bologna L, et al. M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro. J Immunol. 2009;182(7):4415-4422.
15. Koval M, Preiter K, Adles C, Stahl PD, Steinberg TH. Size of IgG-opsonized particles determines macrophage response during internalization. Exp Cell Res. 1998;242(1): 265-273.
16. Kao KJ. Selective elution of HLA antigens and beta 2-microglobulin from human platelets by chloroquine diphosphate. Transfusion. 1988; 28(1):14-17.
17. Kurata Y, Oshida M, Take H, et al. New approach to eliminate HLA class I antigens from platelet surface without cell damage: acid treatment at pH 3.0. Vox Sang. 1989;57(3): 199-204.
18. Novotny VM, Doxiadis IN, van Doorn R, Brand A. The kinetics of HLA class I elution and the relevance for the use of HLA-eluted platelet transfusions. Br J Haematol. 1996;95(2): 416-422.
19. Meinke S, Sandgren P, Mörtberg A, et al. Platelets made HLA deficient by acid treatment aggregate normally and escape destruction by complement and phagocytes in the presence of HLA antibodies. Transfusion. 2016;56(2):370-382, quiz 369.
20. Novotný VM, Doxiadis II, Brand A. The reduction of HLA class I expression on platelets: a potential approach in the management of HLA-alloimmunized refractory patients. Transfus Med Rev. 1999;13(2):95-105.
21. Schiffer CA, O'Connell B, Lee EJ. Platelet transfusion therapy for alloimmunized patients: selective mismatching for HLA B12, an antigen with variable expression on platelets. Blood. 1989;74(3):1172-1176.
22. Schipper RF, Schreuder GM, D'Amaro J, Oudshoorn M. HLA gene and haplotype frequencies in Dutch blood donors. Tissue Antigens. 1996;48(5):562-574.
23. Szatkowski NS, Aster RH. HLA antigens of platelets. IV. Influence of "private" HLA-B locus specificities on the expression of Bw4 and Bw6 on human platelets. Tissue Antigens. 1980;15(4):361-368.
24. Liebert M, Aster RH. Expression of HLA-B12 on platelets, on lymphocytes and in serum: a quantitative study. Tissue Antigens. 1977;9(4): 199-208.
25. Aster RH, Szatkowski N, Liebert M, Duquesnoy RJ. Expression of HLA-B12, HLA-B8, w4, and w5 on platetelets. Transplant Proc. 1977;9(4): 1695-1696.
26. Szatkowski N, Duquesnoy RJ, Aster RH. Further studies of the expression of BW4, BW6, and other antigens of the HLA-B locus on human platelets. Transpl Proc; 1978: 9739-9740
27. Lim J, Kim Y, Han K, et al. Flow cytometric monocyte phagocytic assay for predicting platelet transfusion outcome. Transfusion. 2002;42(3):309-316.
28. van Hensbergen Y, Mulder A, Cornelissen JJ, Brand A. Validation of human monoclonal HLA Class I antibodies to evaluate the kinetics of donor chimerism in different cell subsets after double-cord-blood transplantation in the NOD/SCID model. Transfusion. 2013;53(1): 104-114.
29. Mulder A, Kardol MJ, Arn JS, et al. Human monoclonal HLA antibodies reveal interspecies crossreactive swine MHC class I epitopes relevant for xenotransplantation. Mol Immunol. 2010;47(4):809-815.
30. Dellgren C, Ekwelum VAC, Ormhoj M, et al. Low constitutive cell surface expression of HLA-B is caused by a posttranslational mechanism involving Glu180 and Arg. J Immunol. 197(12):4807-4816.
31. René C, Lozano C, Villalba M, Eliaou J-F. 59 and 39 untranslated regions contribute to the differential expression of specific HLA-A alleles. Eur J Immunol. 2015;45(12): 3454-3463.
32. Isa A, Nehlin JO, Sabir HJ, et al. Impaired cell surface expression of HLA-B antigens on mesenchymal stem cells and muscle cell progenitors. PLoS One. 2010;5(5):e10900.
33. Kelly AM, Garner SF, Herbert N, et al. The effect of variation in donor platelet function on transfusion outcome: a semi-randomised, double blind, controlled trial (PROmPT). Blood. 2014;124(21):595.